Interleukin-10 (IL-10) is a potent inhibitor of leukocyte chemotaxis, bacterial killing in phagocytes and synthesis of pro-inflammatory cytokines and chemokines, and recent studies have suggested an important role for this immunoregulatory cytokine in the pathogenesis of urinary tract infections (UTIs). Therefore, the gene encoding IL-10 (IL10) is an attractive candidate for association studies attempting to identify susceptibility genes conferring risk of UTIs. In this case-control study, we aimed to investigate the association of single nucleotide polymorphisms (SNPs) in the promoter region of IL10 with acute pyelonephritis in the Slovak population. Polymerase chain reaction with sequence-specific primers was used to analyse IL10 -1082A/G (rs1800896), -819C/T (rs1800871) and -592C/A (rs1800872) SNPs in 147 children with acute pyelonephritis and 215 healthy controls. Comparison of patients with healthy controls using the logistic regression analysis revealed significantly increased risk of developing recurrent attacks of acute pyelonephritis for -1082 G allele in a dominant genetic model GG (GG + AG vs. AA, P = 0.019, odds ratio (OR) = 2.26). A similar tendency was also found when the recurrent acute pyelonephritis subgroup was compared to episodic pyelonephritis cases (GG + AG vs. AA, P = 0.009, OR = 3.38). In conclusion, our results suggest that IL10 -1082 A/G SNP is a susceptibility factor for development of recurrent attacks of acute pyelonephritis.

Department of Immunology Faculty of Medicine Comenius University in Bratislava Odborárske nám 14 81108 Bratislava Slovakia

Zobrazit více v PubMed

Transplantation. 2003 Mar 15;75(5):711-7 PubMed

Int J Immunogenet. 2007 Dec;34(6):399-405 PubMed

PLoS One. 2007 Sep 05;2(9):e825 PubMed

Eur J Immunogenet. 1997 Feb;24(1):1-8 PubMed

Front Immunol. 2013 May 31;4:129 PubMed

BMC Bioinformatics. 2008;9 Suppl 1:S2 PubMed

Adv Exp Med Biol. 2013;764:205-10 PubMed

Pediatr Nephrol. 1992 Jan;6(1):19-24 PubMed

J Leukoc Biol. 2001 Jun;69(6):899-906 PubMed

Clin Exp Immunol. 2000 Nov;122(2):200-6 PubMed

Immunity. 2013 Feb 21;38(2):349-59 PubMed

Genes Immun. 2006 Jun;7(4):269-76 PubMed

PLoS One. 2010 Dec 03;5(12):e14223 PubMed

Pediatr Infect Dis J. 2011 Apr;30(4):309-14 PubMed

Genes Immun. 2001 Apr;2(2):61-70 PubMed

Pediatr Res. 2007 Aug;62(2):183-7 PubMed

Eur J Clin Invest. 2008 Oct;38 Suppl 2:29-38 PubMed

PLoS One. 2010 May 20;5(5):e10734 PubMed

Pediatr Res. 2007 Mar;61(3):371-4 PubMed

Arch Virol. 2010 Nov;155(11):1839-42 PubMed

J Biomed Biotechnol. 2010;2010:321082 PubMed

Infection. 2011 Feb;39(1):21-7 PubMed

FEMS Immunol Med Microbiol. 2012 Apr;64(3):295-313 PubMed

Lancet Infect Dis. 2006 Sep;6(9):557-69 PubMed

PLoS One. 2009 Jun 22;4(6):e5990 PubMed

Int J Immunogenet. 2012 Aug;39(4):338-45 PubMed

Int J Antimicrob Agents. 2011 Dec;38 Suppl:51-7 PubMed

J Immunol. 2000 Nov 1;165(9):5287-94 PubMed

Int J Immunogenet. 2012 Aug;39(4):303-7 PubMed

Cytokine Growth Factor Rev. 2010 Oct;21(5):331-44 PubMed

Am J Hum Genet. 2004 Apr;74(4):765-9 PubMed

J Pediatr. 2010 Dec;157(6):1038-1040.e1 PubMed

J Infect Public Health. 2009;2(3):136-40 PubMed

Am J Transplant. 2004 Oct;4(10):1684-90 PubMed

Bioinformatics. 2006 Aug 1;22(15):1928-9 PubMed

Eur J Clin Invest. 2008 Oct;38 Suppl 2:21-8 PubMed

BMJ. 1989 Sep 16;299(6701):703-6 PubMed

Arthritis Rheum. 1999 Jun;42(6):1101-8 PubMed

PLoS One. 2013;8(3):e58687 PubMed

Nat Rev Urol. 2011 Jul 12;8(8):449-68 PubMed

Genes Immun. 1999 Sep;1(1):3-19 PubMed

J Immunol. 2012 Jan 15;188(2):781-92 PubMed

Cytokine. 1996 Sep;8(9):686-97 PubMed

Genes Immun. 2002 Sep;3(6):313-30 PubMed

J Urol. 2007 Mar;177(3):1102-6 PubMed

Curr Opin Microbiol. 2013 Feb;16(1):100-7 PubMed